Photo of Pavel A. Petukhov

Pavel A. Petukhov

Contact

Office Phone:

(312) 996-4174 (work)

Email:

pap4@uic.edu

Related Sites:

About

Overview:
I have a broad background in medicinal chemistry, computer-aided drug design, synthetic organic chemistry, and chemical biology. I received extensive training in synthetic organic chemistry, medicinal chemistry, and computer-aided drug design during my PhD and postdoctoral research. As PI, co-PI, and co-investigator on multiple NIH and DoD-funded grants, I have gained broad experience in design and administration of complex multidisciplinary grants geared toward medicinal chemistry, in silico screening, computer-aided design, chemical biology, design and discovery of novel small molecules as chemical tools to study biology, and discovery and development of novel small molecule-based therapeutic approaches to a variety of diseases and conditions.

Research Interests:
Research in Dr. Petukhov laboratory is focused on (1) the discovery, computational design, synthesis, and preclinical studies of novel small molecule compounds as therapeutics for a variety of diseases and conditions and (2) development of novel chemical tools and approaches to gain deeper understanding of biology. Current projects focus on discovery of novel small molecule therapeutics for the treatment of schistosomiasis, acute myeloid leukemia (AML), and chronic hepatitis B virus infections.

Teaching and Supervision

PSCI Ph.D. Thesis Research (PSCI 599), 6/14/2021 – 8/6/2021
Doctoral Restch in Med Chem (MDCH 599), 1/11/2021 – 4/30/2021
Fundamentals of Drug Action (PHAR 422), 8/24/2020 – 12/4/2020
Fundamentals of Drug Action (PHAR 422), 8/24/2020 – 12/4/2020
Fundamentals of Drug Action (PHAR 422), 8/24/2020 – 12/4/2020
Fundamentals of Drug Action (PHAR 422), 8/24/2020 – 12/4/2020
Doctoral Restch in Med Chem (MDCH 599), 8/24/2020 – 12/4/2020
Drug Design (MDCH 572), 1/13/2020 – 5/1/2020
Doctoral Restch in Med Chem (MDCH 599), 1/13/2020 – 5/1/2020

Selected Grants

Identification of the target of meclonazepam in schistosome worms, National Institute of Allergy and Infectious Diseases., 2/22/2021 - 1/31/2023, Obligated Amount: $251200; No Anticipated Amount Set

Identification of the target of meclonazepam in schistosome worms, Rush University Medical Center., 2/22/2021 - 1/31/2022, Obligated Amount: $79950; Anticipated Amount: $119925

Discovery of novel smHDAC8 inhibitors for the treatment of schistosomiasis, National Institutes of Health (National Institute of Allergy and Infectious Diseases)., 12/4/2020 - 11/30/2022, Obligated Amount: $216651; Anticipated Amount: $447143

Identification of Preclinical Drug Candidates for the Treatment of Schistosomiasis, Rush University Medical Center., 12/1/2018 - 11/30/2021, Obligated Amount: $578006; Anticipated Amount: $578006

Histone deacetylase target engagement as a tool to individualize epigenetics-based therapeutics and decipher their clinical efficacy and toxicity, PhRMA Fdn., 1/1/2018 - 12/31/2018, Obligated Amount: $20000; Anticipated Amount: $20000

Identification of preclinical drug candidates for the treatment of schistosomiasis, National Institute of Allergy and Infectious Diseases., 12/1/2016 - 11/30/2018, Obligated Amount: $391590; No Anticipated Amount Set

Role of Leukocyte-Endothelial Adhesion in Diabetic Retinopathy, National Institutes of Health (National Eye Institute)., 9/30/2015 - 8/31/2021, Obligated Amount: $1913299; Anticipated Amount: $1913299

Generating Human CORD-Blood-Derived Functional Megakaryocytes and Platelets, National Institutes of Health (National Heart, Lung, and Blood Institute)., 9/10/2015 - 5/31/2020, Obligated Amount: $1730126; Anticipated Amount: $1730126

Therapeutic Targeting of Carotid Body for Sleep-Disordered Breathing, University of Chicago., 9/22/2014 - 6/30/2016, Obligated Amount: $1518448; Anticipated Amount: $1518448

Selected Publications

Popova, IA, Lubbe, L, Petukhov, PA, Kalantarov, GF, Trakht, IN, Chernykh, ER, Leplina, OY, Lyubimov, AV, Garcia, JGN, Dudek, SM, Sturrock, ED, Danilov, SM. (2021). Epitope mapping of novel monoclonal antibodies to human angiotensin I-converting enzyme. Protein Science, 30, (8), 1577-1593. doi:10.1002/pro.4091.

Fata, F, Silvestri, I, Ardini, M, Ippoliti, R, Di Leandro, L, Demitri, N, Polentarutti, M, Di Matteo, A, Lyu, H, Thatcher, GRJ, Petukhov, PA, Williams, DL, Angelucci, F. (2021). Probing the Surface of a Parasite Drug Target Thioredoxin Glutathione Reductase Using Small Molecule Fragments. ACS Infectious Diseases, 7, (7), 1932-1944. doi:10.1021/acsinfecdis.0c00909.

Danilov, SM, Jain, MS, Petukhov, PA, Goldman, C, DiSanto-Rose, M, Vancavage, R, Francuzevitch, LY, Samokhodskaya, LM, Kamalov, AA, Arbieva, ZH, Sturrock, ED, Dudek, SM, Judson, MA. (2021). Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels. Translational Research, 230, 5-20. doi:10.1016/j.trsl.2020.07.010.

Bertels, Z, Singh, H, Dripps, I, Siegersma, K, Tipton, AF, Witkowski, W, Sheets, Z, Shah, P, Conway, C, Mangutov, E, Ao, M, Petukhova, V, Karumudi, B, Petukhov, PA, Baca, SM, Rasenick, MM, Pradhan, AA. (2021). Neuronal complexity is attenuated in preclinical models of migraine and restored by hdac6 inhibition. eLife, 10. doi:10.7554/ELIFE.63076.

Taha, TY, Anirudhan, V, Limothai, U, Loeb, DD, Petukhov, PA, McLachlan, A. (2020). Modulation of hepatitis B virus pregenomic RNA stability and splicing by histone deacetylase 5 enhances viral biosynthesis. PLoS Pathogens, 16, (8). doi:10.1371/journal.ppat.1008802.

Lyu, H, Petukhov, PA, Banta, PR, Jadhav, A, Lea, WA, Cheng, Q, Arnér, ESJ, Simeonov, A, Thatcher, GRJ, Angelucci, F, Williams, DL. (2020). Characterization of Lead Compounds Targeting the Selenoprotein Thioredoxin Glutathione Reductase for Treatment of Schistosomiasis. ACS Infectious Diseases, 6, (3), 393-405. doi:10.1021/acsinfecdis.9b00354.

Silvestri, I, Lyu, H, Fata, F, Banta, PR, Mattei, B, Ippoliti, R, Bellelli, A, Pitari, G, Ardini, M, Petukhova, V, Thatcher, GRJ, Petukhov, PA, Williams, DL, Angelucci, F. (2020). Ectopic suicide inhibition of thioredoxin glutathione reductase. Free Radical Biology and Medicine, 147, 200-211. doi:10.1016/j.freeradbiomed.2019.12.019.

Taha, TY, Aboukhatwa, SM, Knopp, RC, Ikegaki, N, Abdelkarim, H, Neerasa, J, Lu, Y, Neelarapu, R, Hanigan, TW, Thatcher, GRJ, Petukhov, PA. (2019). Correction: Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors (ACS Medicinal Chemistry Letters (2017) 8: 8 (824−829) DOI: 10.1021/acsmedchemlett.7b00126). ACS Medicinal Chemistry Letters, 10, (9), 1358. doi:10.1021/acsmedchemlett.9b00336.

Aboukhatwa, SM, Hanigan, TW, Taha, TY, Neerasa, J, Ranjan, R, El-Bastawissy, EE, Elkersh, MA, El-Moselhy, TF, Frasor, J, Mahmud, N, McLachlan, A, Petukhov, PA. (2019). Structurally Diverse Histone Deacetylase Photoreactive Probes: Design, Synthesis, and Photolabeling Studies in Live Cells and Tissue. ChemMedChem, 14, (11), 1096-1107. doi:10.1002/cmdc.201900114.